RWE’s Biggest Role In US FDA Approvals: External Controls For Breakthrough Rare Disease Therapies
Executive Summary
Despite broad interest, real-world evidence of efficacy in FDA decisions remains largely limited to orphan diseases and natural history, a Pink Sheet analysis shows.
You may also be interested in...
Honoring R&D Excellence: Citeline Awards Nominations Are Open
The Citeline Awards celebrate the efforts of biopharma research and development communities, with 12 categories ranging from use of technology to quality results. Nominations are open through 20 January 2023.
Honoring R&D Excellence: Citeline Awards Nominations Are Open
The Citeline Awards celebrate the efforts of biopharma research and development communities, with 12 categories ranging from use of technology to quality results. Nominations are open through 20 January 2023.
Keeping Track: Immunology Drives US FDA Action, With Approvals For AZ/Amgen’s Tezspire, Argenx’s Vyvgart, And New JAK Uses
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker